SELLAS Life Sciences Group, Inc.
SLS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001390478
No open-market purchases or sales by SELLAS Life Sciences Group, Inc. insiders were filed in the last 90 days; 193 institutions reported holding it in 13F filings for Q2 2026, worth $1.08B in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding SELLAS Life Sciences Group, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 26 | 28 | +2 |
| Shares | 2.98M | 2.19M | −792.4K (−26.6%) |
| Value | $6.64M | $4.42M | −$2.22M (−33.5%) |
New holders (5)
Institutions that held SELLAS Life Sciences Group, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Millennium Management LLC | 24,783 | $50.0K | 0.00% |
| Charles Schwab Investment Management Inc | 16,238 | $33.0K | 0.00% |
| CWM, LLC | 2,000 | $4.00K | 0.00% |
| UBS Group AG | 1,359 | $3.00K | 0.00% |
| Simplex Trading, LLC | 1,315 | $2.00K | 0.00% |
Sold out (3)
Institutions that held SELLAS Life Sciences Group, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Alyeska Investment Group, L.P. | 254,018 | $566.0K |
| Bank of America Corp | 24,268 | $54.0K |
| Cubist Systematic Strategies, LLC | 10,100 | $23.0K |